Remicade

ApprovedBiologic

Merck & Co.

Remicade is one of 193 biologic programs targeting Takayasu arteritis. It is currently in Approved.

Indications

Total Trials

Active Trials

192

Competitors

Pipeline

Status by Indication[3][1]

Indication

Takayasu ArteritisActive, not recruiting

Kidney TransplantActive, not recruiting

Inflammatory Bowel DiseaseActive, not recruiting

Rheumatoid ArthritisActive, not recruiting

Psoriatic ArthritisActive, not recruiting

Ankylosing SpondylitisActive, not recruiting

UveitisActive, not recruiting

Takayasu ArteritisPhase 2

Active, not recruiting

Kidney TransplantPreclinical

Active, not recruiting

Inflammatory Bowel DiseasePreclinical

Active, not recruiting

Rheumatoid ArthritisPhase 3

Active, not recruiting

Psoriatic ArthritisPreclinical

Active, not recruiting

Ankylosing SpondylitisApproved

Active, not recruiting

UveitisPreclinical

Active, not recruiting

Competition

Competitive Landscape

791 competitors in Rheumatoid Arthritis

#DrugCompanyPhaseTrials

Remicade

Merck & Co.

Approved

8 2

Orencia

Bristol-Myers Squibb

Preclinical

47 3

Actemra

Cimzia

30 5

Simponi

Johnson & Johnson

Preclinical

19 6

Ilaris

Novartis

Preclinical

3 7

Actos

Takeda

Preclinical

2 8

Celexa

AbbVie

Preclinical

1 9

Kineret

SSwedish Orphan Biovitrum

Preclinical

6 10

Velcade

SShilpa Grover, MD, MPH

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Rheumatoid Arthritis8 trials

BOW015 (Infliximab-EPIRUS) and Infliximab in Patients With Active Rheumatoid Arthritis: The UNIFORM Study

Unknown status·EEpirus Biopharmaceuticals (Switzerland) GmbH·Phase 3·NCT02683564·548 enrolled

A Randomized, Multi-Center Biomarker Trial to Predict Therapeutic Responses of Patients With Rheumatoid Arthritis to a Specific Biologic Mode of Action

Completed·MMedical University of Vienna·Phase 4·NCT01638715·115 enrolled

Sleep and Immunity in Rheumatoid Arthritis : Remicade Substudy

Completed·UUniversity of California, Los Angeles·N/A·NCT00948610·20 enrolled

Show 5 more trials

To Compare the Efficacy, Pharmacokinetics and Safety Between CT-P13 and China Approved Remicade When Co-administered With Methotrexate in Patients With Active Rheumatoid Arthritis

Completed·CCelltrion·Phase 3·NCT03707535·270 enrolled

A Study Comparing SB2 to Remicade® in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy

Completed·SSamsung Bioepis Co., Ltd.·Phase 3·NCT01936181·584 enrolled

CMAB008 With MTX Therapy in Adult Patients With Moderately to Severely Active Rheumatoid Arthritis

Completed·SShanghai Biomabs Pharmaceutical Co., Ltd.·Phase 3·NCT03478111·390 enrolled

A Phase 3 Study of NI-071 in Participants With Rheumatoid Arthritis (RADIANCE)

Completed·NNichi-Iko Pharmaceutical Co., Ltd.·Phase 3·NCT02990806·683 enrolled

Comparative Clinical Trial of Efficacy and Safety of BCD-055 and Remicade® in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis

Completed·BBiocad·Phase 3·NCT02762838·426 enrolled

Crohn's Disease4 trials

Postmarketing Safety Surveillance European Registry of Crohn's Disease Patients Treated With Remicade or Standard Therapy (MK-2155-035)

Completed· Merck & Co. logo

Merck & Co.··NCT00705614·2,662 enrolled

Demonstrate Noninferiority in Efficacy and to Assess Safety of CT-P13 in Patients With Active Crohn's Disease

Completed·CCelltrion·Phase 3·NCT02096861·220 enrolled

Remicade Safety Line (Crohn's Disease)(Study P03288)(COMPLETED)

Completed· Merck & Co. logo

Merck & Co.··NCT00818272·148 enrolled

Show 1 more trial

Understanding the Relationship Between Infliximab Levels to Clinical Response of Remicade in Crohn's Disease

Terminated·SShradha Agarwal·N/A·NCT01438151·11 enrolled

Ankylosing Spondylitis3 trials

Analysis of the Peripheral Blood Mononuclear Cells of Patients With Ankylosing Spondylitis During Infliximab Treatment (Study P04465)(COMPLETED)

Completed· Merck & Co. logo

Merck & Co.·Phase 4·NCT00778869·10 enrolled

Growth Factor Concentration to Predict an Ankylosing Spondylitis Patient's Response to Infliximab (Study P04041)(COMPLETED)

Completed· Merck & Co. logo

Merck & Co.·Phase 4·NCT00779935·44 enrolled

Comparative Clinical Trial to Evaluate Efficacy and Safety of BCD-055 and Remicade® in Patients With Ankylosing Spondylitis

Completed·BBiocad·Phase 3·NCT02762812·199 enrolled

Uveitis1 trial

A Clinical Trial of Infliximab for Uveitis

Completed·OOregon Health and Science University·N/A·NCT00273390·32 enrolled

Takayasu arteritis1 trial

Clinical Study of Anti-tumor Necrosis Factor Therapy in Patients With Takayasu Arteritis

Unknown status·SSeoul National University Hospital·Phase 2·NCT02457585·11 enrolled

4 more indications

Psoriatic Arthritis1 trial

Investigation of 9 Consecutive Infusions of Remicade for Psoriatic Arthritis in Austria (Study P04264)

Completed· Merck & Co. logo

Merck & Co.··NCT00725296·178 enrolled

Inflammatory Bowel Disease1 trial

Post-Marketing Use Of CT-P13 (Infliximab) For Standard Of Care Treatment Of Inflammatory Bowel Disease

Completed· Pfizer logo

Pfizer··NCT02539368·2,565 enrolled

Kidney Transplant1 trial

Sequential Targeting of Cluster of Differentiation 52 (CD52) and Tumor Necrosis Factor (TNF) Allows Early Minimization Therapy in Kidney Transplantation

Completed·IInstitute for Clinical and Experimental Medicine·N/A·NCT02711202·20 enrolled

Infliximab1 trial

A Pharmacokinetics Study Comparing PF-06438179 and Infliximab in Healthy Volunteers (REFLECTIONS B537-01)

Completed· Pfizer logo

Pfizer·Phase 1·NCT01844804·146 enrolled

Sources

References

[1]
ClinicalTrials.gov — 21 trial records for Remicade. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Remicade compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Remicade. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Merck & Co. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Approved[1]
Company: Merck & Co.

Remicade

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Rheumatoid Arthritis8 trials

Crohn's Disease4 trials

Ankylosing Spondylitis3 trials

Uveitis1 trial

Takayasu arteritis1 trial

Psoriatic Arthritis1 trial

Inflammatory Bowel Disease1 trial

Kidney Transplant1 trial

Infliximab1 trial

References

Drug Info

Quick Facts

Related News